News & Events

MMRF CoMMpass and MyDRUG Studies Drive Discoveries in Research Presented at 19th IMS Annual Meeting

CoMMpass data fuels 19 IMS abstracts, advancing new research and delivering meaningful insights to the myeloma research community

Results from the MyDRUG platform trial show the promise of MEK Inhibitor cobimetinib for myeloma patients with NRAS/KRAS/B-RAF mutations

Norwalk, Conn., August 24, 2022— Today, the Multiple Myeloma Research Foundation (MMRF) announced that new insights and hypotheses related to predictive biomarkers, disease progression, therapeutic resistance, risk assessment, and personalized medicine were generated using data from its landmark CoMMpass StudySM. The findings will be presented at the 19th International Myeloma Society (IMS) Annual Meeting in Los Angeles from August 25 – 27, 2022.

Data from the CoMMpass study are cited in 19 abstracts, four of which were selected to be oral presentations, demonstrating its value in driving new advancements across multiple myeloma research. CoMMpass represents the largest longitudinal genomic data set in multiple myeloma and has led to groundbreaking discoveries that have transformed how researchers understand the biology of multiple myeloma.

“Our mission is to accelerate a cure for each and every myeloma patient,” said Michael Andreini, President and CEO of the MMRF. “Research presented at this year’s IMS Annual Meeting reaffirms our commitment to building models and resources for the myeloma research community that drive progress for patients and new opportunities for researchers. We are thrilled that the CoMMpass study has been used by hundreds of researchers worldwide and continues to generate meaningful learnings that have played a vital role in accelerating the pace of research that can now be translated to clinical care.”

Notable findings at this year’s IMS meeting that incorporate CoMMpass data include:

“Despite great strides in treatment, multiple myeloma remains incurable and often fatal, which is why the use of CoMMpass data, presented in 19 abstracts at the 19th IMS Annual Meeting, further validates the value and utility of our comprehensive genomic and clinical CoMMpass data,” said Hearn Jay Cho, MD, PhD, Chief Medical Officer of the MMRF. “CoMMpass continues to be one of the most important drivers of myeloma research. The MMRF is committed to working closely with researchers across the globe to drive breakthroughs using CoMMpass data, with the goal of bringing us closer to accelerating a cure for every myeloma patient.”

The CoMMpass study currently includes an estimated 1,150 patients spanning 76 sites worldwide and it continues to grow in impact as the data matures.

The IMS meeting will also feature data being presented from MyDRUGSM, a first-in-myeloma Phase 1/2 platform clinical trial conducted in the Multiple Myeloma Research Consortium (MMRC). MyDRUG builds upon discoveries of common cancer-associated mutations in CoMMpass. Targeted therapies specific to some of these mutations are approved in other types of cancer. The goal of MyDRUG is to determine if precision medicine strategies using these targeted therapies are safe and effective in myeloma patients with these mutations.

The study team will report on one sub-protocol of MyDRUG for patients with mutations in NRAS, KRAS, or BRAF. The MEK inhibitor cobimetinib is approved in skin cancer for patients with these mutations. The investigators will present safety and efficacy data of cobimetinib in combination with a standard-of-care, all-oral regimen of ixazomib (Ninlaro), pomalidomide (Pomalyst) and dexamethasone.

About the MMRF CoMMpass StudySM

The MMRF CoMMpass Study is a longitudinal study of patients with newly diagnosed active multiple myeloma. The goal is to map the genomic profile of each patient at diagnosis and each relapse to clinical outcomes in order to develop a more complete understanding of how patients respond to treatments.

About the MMRF MyDRUG StudySM

The MMRF MyDRUG study is the first platform trial in myeloma. The purpose of MyDRUG is to test targeted therapies not yet approved in myeloma, in combination with a standard of care oral triplet therapy, in functionally high-risk multiple myeloma patients who demonstrate specific genetic alterations.

About the Multiple Myeloma Research Foundation (MMRF)

A pioneer in personalized medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of personalized treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the benchmark business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring more than 15 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset in myeloma. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making personalized medicine possible for all patients. The MMRF has raised more than $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit


Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
[email protected]